[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA47460A - Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase - Google Patents

Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase

Info

Publication number
MA47460A
MA47460A MA047460A MA47460A MA47460A MA 47460 A MA47460 A MA 47460A MA 047460 A MA047460 A MA 047460A MA 47460 A MA47460 A MA 47460A MA 47460 A MA47460 A MA 47460A
Authority
MA
Morocco
Prior art keywords
aminotriazolopyridines
kinase inhibitors
kinase
inhibitors
aminotriazolopyridines used
Prior art date
Application number
MA047460A
Other languages
English (en)
Inventor
Murugaiah Subbaiah Murugaiah Andappan
Jie Chen
Carolyn Diane Dzierba
Junqing Guo
Amy C Hart
Guanglin Luo
John E Macor
Michael E Mertzman
William J Pitts
Jianliang Shi
Sing-Yuen Sit
Steven H Spergel
Scott Hunter Watterson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA47460A publication Critical patent/MA47460A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA047460A 2017-02-13 2018-02-12 Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase MA47460A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13

Publications (1)

Publication Number Publication Date
MA47460A true MA47460A (fr) 2019-12-18

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047460A MA47460A (fr) 2017-02-13 2018-02-12 Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase

Country Status (24)

Country Link
US (2) US10913738B2 (fr)
EP (1) EP3580220B1 (fr)
JP (1) JP7097373B2 (fr)
KR (1) KR102549952B1 (fr)
CN (1) CN110520423B (fr)
AU (1) AU2018217488B2 (fr)
BR (1) BR112019016635A2 (fr)
CA (1) CA3053484A1 (fr)
CY (1) CY1124978T1 (fr)
DK (1) DK3580220T3 (fr)
EA (1) EA039808B1 (fr)
ES (1) ES2902676T3 (fr)
HR (1) HRP20212000T1 (fr)
HU (1) HUE057801T2 (fr)
IL (1) IL268614B (fr)
LT (1) LT3580220T (fr)
MA (1) MA47460A (fr)
MX (1) MX2019009555A (fr)
PL (1) PL3580220T3 (fr)
PT (1) PT3580220T (fr)
RS (1) RS62801B1 (fr)
SG (1) SG11201907335UA (fr)
SI (1) SI3580220T1 (fr)
WO (1) WO2018148626A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019009555A (es) * 2017-02-13 2019-10-02 Bristol Myers Squibb Co Aminotriazolopiridinas como inhibidores de cinasa.
LT3704118T (lt) * 2017-10-30 2022-02-25 Bristol-Myers Squibb Company Aminoimidazopiridazinai, kaip kinazės inhibitoriai
BR112020014516A2 (pt) 2018-01-26 2020-12-08 Bristol-Myers Squibb Company Aminopirrolotriazinas como inibidores de quinase
US11993581B2 (en) 2018-07-09 2024-05-28 Lieber Institue, Inc Pyridazine compounds for inhibiting Nav1.8
US12084426B2 (en) 2018-09-13 2024-09-10 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
EP3901147B1 (fr) * 2019-01-25 2023-11-22 Beijing Scitech-MQ Pharmaceuticals Limited Composé hétérocyclique à pont acylamino, composition et utilisation associées
US20220177462A1 (en) * 2019-03-22 2022-06-09 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof
JP7441477B2 (ja) * 2020-02-13 2024-03-01 ▲勁▼方医▲薬▼科技（上海）有限公司 ジヒドロナフチリドン系化合物、その調製方法及び医薬への使用
CN114262322A (zh) * 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
KR102707109B1 (ko) 2021-08-10 2024-09-20 애브비 인코포레이티드 니코틴아미드 ripk1 억제제
CN118647617A (zh) 2022-03-16 2024-09-13 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用
CN114989079B (zh) * 2022-06-21 2023-06-23 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
WO2024146945A1 (fr) 2023-01-07 2024-07-11 Syngenta Crop Protection Ag Nouveaux composés pesticides à base de carboxamide et de sulfonamide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765825A1 (fr) 2004-06-25 2007-03-28 Amgen Inc. Triazols et indazols condenses convenant pour le traitement de maladies induites par les citokines et autres pathologies
WO2007117465A2 (fr) * 2006-03-31 2007-10-18 Abbott Laboratories Composés d'indazole
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CN101952285A (zh) 2007-11-27 2011-01-19 塞尔卓姆有限公司 作为pi3k抑制剂的氨基三唑
WO2010007100A1 (fr) * 2008-07-15 2010-01-21 Cellzome Ltd Amino triazoles substitués en position 7 en tant qu’inhibiteurs de pi3k
WO2010057877A1 (fr) 2008-11-18 2010-05-27 Cellzome Limited Triazolo[1,5-a]pyridines 7-pyridinyle- ou phényl-substituées comme inhibiteurs de pi3k
EP2393813B1 (fr) 2009-02-04 2013-07-31 Vitae Pharmaceuticals, Inc. Inhibiteurs cycliques de 11 ß-hydroxystéroïde déshydrogénase 1, utiles pour le traitement de maladies reliés au niveau élevé de cortisol
EP2897949B1 (fr) 2012-09-18 2018-01-10 Bristol-Myers Squibb Company Antagonistes d'iap
TN2015000542A1 (en) 2013-06-10 2017-04-06 Bayer Pharma AG Novel compounds for the treatment of cancer
BR112017003546A2 (pt) * 2014-08-21 2017-12-05 Glaxosmithkline Ip Dev Ltd amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
WO2017077968A1 (fr) * 2015-11-05 2017-05-11 住友化学株式会社 Composé hétérocyclique condensé
WO2018017435A1 (fr) 2016-07-22 2018-01-25 Accro Bioscience Inc. Composés hétéroaryliques utilisés comme inhibiteurs de la nécrose, composition et application associées
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
MX2019009555A (es) * 2017-02-13 2019-10-02 Bristol Myers Squibb Co Aminotriazolopiridinas como inhibidores de cinasa.
LT3704118T (lt) 2017-10-30 2022-02-25 Bristol-Myers Squibb Company Aminoimidazopiridazinai, kaip kinazės inhibitoriai
BR112020014516A2 (pt) 2018-01-26 2020-12-08 Bristol-Myers Squibb Company Aminopirrolotriazinas como inibidores de quinase
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
BR112019016635A2 (pt) 2020-04-07
ES2902676T3 (es) 2022-03-29
CA3053484A1 (fr) 2018-08-16
PT3580220T (pt) 2022-01-03
EA039808B1 (ru) 2022-03-16
US20220315580A1 (en) 2022-10-06
EP3580220A1 (fr) 2019-12-18
CN110520423A (zh) 2019-11-29
KR20190117006A (ko) 2019-10-15
HRP20212000T1 (hr) 2022-04-01
CN110520423B (zh) 2022-08-23
MX2019009555A (es) 2019-10-02
RS62801B1 (sr) 2022-02-28
LT3580220T (lt) 2021-12-27
US10913738B2 (en) 2021-02-09
CY1124978T1 (el) 2023-01-05
WO2018148626A1 (fr) 2018-08-16
KR102549952B1 (ko) 2023-06-29
AU2018217488B2 (en) 2021-09-23
US20190389859A1 (en) 2019-12-26
AU2018217488A1 (en) 2019-10-03
EP3580220B1 (fr) 2021-11-17
SI3580220T1 (sl) 2022-01-31
EA201991915A1 (ru) 2019-12-30
PL3580220T3 (pl) 2022-02-07
DK3580220T3 (da) 2022-01-10
JP2020507582A (ja) 2020-03-12
JP7097373B2 (ja) 2022-07-07
IL268614B (en) 2021-12-01
IL268614A (en) 2019-10-31
SG11201907335UA (en) 2019-09-27
HUE057801T2 (hu) 2022-06-28

Similar Documents

Publication Publication Date Title
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
MA53110A (fr) Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1